Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: A prospective, nonrandomized, crossover study in patients coinfected with hepatitis c and hiv receiving methadone maintenance treatment

Clinical Therapeutics

Volumn 29, Issue 1, 2007, Pages 131-138

  Berk, Steven I ^a   Litwin, Alain H ^a   Arnsten, Julia H ^a   Du, Evelyn ^a   Soloway, Irene ^a   Gourevitch, Marc N ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hepatitis C; HIV; methadone; pegylated interferon

Indexed keywords

ABACAVIR; AMINOTRANSFERASE; ATAZANAVIR; LAMIVUDINE; METHADONE; PEGINTERFERON ALPHA2B; RIBAVIRIN; ZIDOVUDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; ELECTROLYTE BLOOD LEVEL; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE INFLAMMATION; KIDNEY FUNCTION; MALE; METHADONE TREATMENT; MYALGIA; OBJECTIVE OPIATE WITHDRAWAL SCALE; PROSPECTIVE STUDY; SIDE EFFECT; SUBJECTIVE OPIATE WITHDRAWAL SCALE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; ANTIVIRAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; METHADONE; MIDDLE AGED; PROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33947257773     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.01.009     Document Type: Article

References (44)

1. Murrill C.S., Weeks H., Castrucci B.C., et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health 92 (2002) 385-387
2. Lorvick J., Kral A.H., Seal K., et al. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 91 (2001) 46-47
3. Piccolo P., Borg L., Lin A., et al. Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment. J Addict Dis 21 (2002) 55-66
4. Sherman K.E., Rouster S.D., Chung R.T., and Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodefciency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 34 (2002) 831-837
5. Sulkowski M.S., and Thomas D.L. Hepatitis C in the HIV-infected person. Ann Intern Med 138 (2003) 197-207
6. Taylor L.E. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 40 Suppl 5 (2005) 5355-5361
7. Lucas G.M., Weidle P.J., Hader S., and Moore R.D. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clin Infect Dis 38 Suppl 5 (2004) 5409-5413
8. Litwin A.H., Soloway I., and Gourevitch M.N. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities. Clin Infect Dis 40 Suppl 5 (2005) S339-S345
9. Manns M.P., McHutchison J.G., Gordon S.C., et al. for the International Hepatitis Interventional Therapy Group. Peginterferon alfa-26 plus ribavirin compared with interferon alfa-26 plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358 (2001) 958-965
10. Edlin B.R., Seal K.H., Lorvick J., et al. Is itjustifiable to withhold treatment for hepatitis C from illicit-drug users?. N Engl J Med 345 (2001) 211-215
11. [published correction appears in N Engl J Med. 2001;345:1716]. Davis G.L., and Rodrigue J.R. Treatment of chronic hepatitis C in active drug users. N Eng J Med. 345 (2001) 215-217
12. Sylvestre D.L., Litwin A.H., Clements B.J., and Gourevitch M.N. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 29 (2005) 159-165
13. Bruce R.D., Altice F.L., Gourevitch M.N., and Friedland G.H. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Def c Syndr 41 (2006) 563-572
14. Iribarne C., Berthou F., Baird S., et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9 (1996) 365-373
15. Moody D.E., Alburges M.E., Parker R.J., et al. The involvement of cytochrome P450 3A4 in the N-demethylation of l-alpha-acetylmethadol (LRAM), norLAAM, and methadone. Drug Metab Dispos 25 (1997) 1347-1353
16. Wang J.S., and DeVane C.L. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 31 (2003) 742-747
17. Kreek M.J., Garfield J.W., Gutjahr C.L., and Giusti L.M. Rifampininduced methadone withdrawal. N Engl J Med 294 (1976) 1104-1106
18. Luvox (fluvoxamine) [product information] (1996), Solvay Pharmaceuticals, Inc, Marietta, Ga
19. Moore J.A., Marafino Jr. B.J., and Stebbing N. Influence of various purified interferons on effects of drugs in mice. Res Commun Chem Pathol Pharmacol 39 (1983) 113-125
20. Williams S.J., and Farrell G.C. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 22 (1986) 610-612
21. Williams S.J., Baird-Lambert J.A., and Farrell G.C. Inhibition of theophylline metabolism by interferon. Lancet 2 (1987) 939-941
22. Jonkman J.H., Nicholson K.G., Farrow P.R., et al. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. BrJ Clin Pharmacol 27 (1989) 795-802
23. Okuno H., Kitao Y., Takasu M., et al. Depression of drug metabolizing activity in the human liver by interferonalpha. Eur J Clin Pharmacol 39 (1990) 365-367
24. Okuno H., Takasu M., Kano H., et al. Depression of drugmetabolizing activity in the human liver by interferonbeta. Hepatology 17 (1993) 65-69
25. Islam M., Frye R.F., Richards T.J., et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: A potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 8 (2002) 2480-2487
26. Engel G., Hofmann U., Heidemann H., et al. Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59 (1996) 613-623
27. Echizen H., Ohta Y., Shirataki H., et al. Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis. J Clin Pharmacol 30 (1990) 562-567
28. Sieck J.O., el-Yazigi A., Ali H., et al. Elimination of antipyrine and its metabolites in interferon treated hepatitis C. Hum Exp Toxicol 13 (1994) 598-601
29. Coverdale S., Byth K., Field J., et al. Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatology 22 (1995) 1065-1071
30. Williams S.J., and Farrell G.C. Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferoninduced changes in chronic hepatitis B disease activity. Hepatology 10 (1989) 192-197
31. Zeuzem S., Welsch C., and Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 23 Suppl 1 (2003) 23-28
32. Sulkowski M., Wright T., Rossi S., et al. Peginterferon alfa-2a does not alter the pharmacokinetics of metha done in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 77 (2005) 214-224
33. Available at:. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Accessed November 15, 2006 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int
34. Available at:. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Bio medical Research Involving Human Subjects [WMA Web site]. FerneyVoltaire. Accessed November 15, 2006. (1989), WMA, France. http://www.wma.net
35. Sheehan D.V., Lecrubier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric inter view for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl 20 (1998) 22-33
36. (peginterferon alfa-2b) [product information]. Peg-Intron (2003), Schering-Plough Corp, Kenilworth, NJ
37. Berk S.I., Litwin A.H., Du Y., Cruikshank G., et al. False reduction in serum methadone concentrations by BD Vacutainer serum separator tubes (SST). Clin Chem 52 (2006) 1972-1974
38. McCance-Katz E.F., Rainey P.M., Friedland G., and Jadow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 37 (2003) 476-482
39. Handelsman L., Cochrane K.J., Aronson M.J., et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13 (1987) 293-308
40. Lightfoot S.L., and Oliver J.M. The Beck Inventory: Psychometric properties in university students. J Pers Assess 49 (1985) 434-436
41. Schaefer M., Schmidt F., Folwaczny C., et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37 (2003) 443-451
42. Mauss S., Berger F., Goelz J., et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 40 (2004) 120-124
43. Hamilton S.P., Nunes E.V., Janal M., and Weber L. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 9 (2000) 63-69
44. Cobb M.N., Desai J., Brown Jr. L.S., et al. The effect of fluconazole on the clinical pharmacokinetics of metha done. Clin Pharmacol Ther 63 (1998) 655-662